Hydrocortancyl (Prednisolone Acetate)

Hydrocortancyl is employed in clinical practice for conditions where localized anti‑inflammatory or immunosuppressive therapy is required.

• Management of acute inflammatory joint disorders such as synovitis or bursitis when administered intra‑articularly.
• Treatment of spinal nerve root inflammation or radiculopathy via epidural injection.
• Control of localized skin or soft‑tissue lesions, including keloids or hypertrophic scars, through intralesional delivery.
• Adjunctive therapy for postoperative inflammation in orthopedic procedures.
• Temporary relief of severe localized allergic reactions when other routes are unsuitable.

• Prednisolone acetate exerts its effect by diffusing across cell membranes and binding to intracellular glucocorticoid receptors. The receptor‑ligand complex translocates to the nucleus, where it interacts with glucocorticoid response elements on DNA, modulating transcription of multiple genes. This results in decreased synthesis of pro‑inflammatory cytokines, inhibition of phospholipase A2, and reduced migration of immune cells, collectively producing anti‑inflammatory and immunosuppressive actions.

Adverse reactions to Hydrocortancyl may vary in frequency and severity, reflecting the systemic activity of corticosteroids delivered locally.

Common

• Transient pain or swelling at the injection site.
• Temporary increase in local skin pigmentation.
• Mild elevation of blood glucose in susceptible individuals.
• Brief headache or dizziness following epidural administration.

Serious

• Infection at the injection site, including cellulitis or abscess formation.
• Significant suppression of the hypothalamic‑pituitary‑adrenal axis leading to adrenal insufficiency.
• Ocular complications such as increased intra‑ocular pressure or cataract formation with repeated use.

Because Hydrocortancyl delivers a potent glucocorticoid directly into tissues, several precautionary measures should be observed before and during therapy.

• Verify patient history for systemic infections, uncontrolled diabetes, or active tuberculosis.
• Avoid use in patients with known hypersensitivity to prednisolone acetate or other corticosteroids.
• Assess ocular health prior to repeated intra‑articular injections, especially in glaucoma patients.
• Use the lowest effective dose and limit the frequency of injections to reduce systemic exposure.
• Monitor adrenal function when treatment extends beyond a few weeks.
• Counsel pregnant or breastfeeding women that safety data are limited and the drug should be used only if clearly indicated.

Hydrocortancyl can interact with other medicines that influence corticosteroid metabolism or amplify immunosuppressive effects.

Avoid

• Concurrent systemic corticosteroids, which may increase the risk of adrenal suppression.
• Strong CYP3A4 inducers such as rifampin or phenytoin, which can reduce prednisolone acetate levels.
• Live vaccines, because immunosuppression may diminish vaccine efficacy.

Use with caution

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) or anticoagulants, due to potential additive gastrointestinal bleeding risk.
• Antidiabetic agents, as corticosteroid exposure may worsen glycemic control.
• Antifungal azoles (e.g., ketoconazole) that inhibit CYP3A4, potentially raising systemic corticosteroid concentrations.